Navigation Links
Schering-Plough Reports Financial Results for 2009 First Quarter
Date:4/21/2009

ares in approximately 50 percent of the profits of the joint venture with Merck, although there are different profit-sharing arrangements for the cholesterol products in countries around the world. Schering-Plough records its share of the income from operations in "Equity income," which totaled $400 million in the 2009 first quarter, as compared to $517 million in the first quarter of 2008.

Schering-Plough does not record sales of its cholesterol joint venture and incurs substantial costs such as selling, general and administrative costs that are not reflected in "Equity income" and are borne by the overall cost structure of Schering-Plough. As a result, Schering-Plough's gross margin and ratios of selling, general and administrative (SG&A) expenses and R&D expenses as a percentage of sales do not reflect the benefit of the impact of the cholesterol joint venture's operating results.

Schering-Plough's gross margin on a GAAP basis was unfavorably affected by purchase accounting adjustments and totaled 68.2 percent for the 2009 first quarter as compared to 54.1 percent in the 2008 period. Excluding purchase accounting adjustments, the gross margin percentage increased to 71.0 percent for the first quarter of 2009 as compared to 68.9 percent for the first quarter of 2008, primarily due to a favorable impact from foreign exchange.

SG&A expenses were $1.5 billion in the first quarter of 2009, an 11 percent decrease versus the first quarter of 2008 primarily due to the impact of foreign exchange and PTP actions.

Research and development spending for the 2009 first quarter totaled $804 million, a 9 percent decline due to PTP actions, the impact of foreign exchange and the timing of clinical trials and related activities.

Update on Merger with Merck

The previously announced merger with Merck remains on track. Merger pre-integration planning teams h
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year
2. Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M.
3. Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
4. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
5. Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
6. Schering-Plough Selects Benefit Advocates for Health Advocacy
7. Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
8. Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
9. Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
10. Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
11. Schering-Plough to Webcast R&D Update Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Steven Reinberg HealthDay ... The number of U.S. teens using sunscreen dropped nearly 12 ... During that same time period, the number of teens using ... to use sunscreen increase the risk of skin cancers, including ... decrease in the overall percentage of teens who reported wearing ...
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... work in family and product liability law, announces the ... The website provides comprehensive information on morcellator surgery ... the April 2014 FDA morcellator cancer warning and the ... news release* accompanying the April 17, 2014 FDA warning ...
(Date:8/21/2014)... announces the immediate release of Care of the ... CHEST Consensus Statement today in the Online First ... the global health-care community cares for patients with ... guide ethical decision-making, coordination of care, resource conservation, ... by over 100 clinicians and experts representing a ...
(Date:8/21/2014)... international scientific collaboration led by Baylor College of Medicine ... to a rare form of kidney cancer, providing new ... types as well. , The collaboration, a project of ... initiative , completed the sequence of chromophobe renal cell ... Cancer Cell . , "The Cancer Genome ...
(Date:8/21/2014)... have developed a genetically engineered line of mice that ... on epilepsy, Alzheimer,s and other diseases. , The ... of fluorescence in response to different calcium levels. This ... and microglia, to be studied in a new way. ... how the brain works," said Petr Tvrdik, Ph.D., ...
Breaking Medicine News(10 mins):Health News:Fewer U.S. Teens Using Sunscreen, Study Finds 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 2Health News:The Onder Law Firm Launches National Morcellator Cancer Lawsuit Center Website for Morcellator Surgery Lawsuits at MorcellatorCancerLawsuitCenter.com 3Health News:CHEST releases new expert guidance in care of the critically ill and injured 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2
... found that radiotherapy given in large dosage but in small ... UK and US said that 13 larger doses were found ... to the conventional regime of 25 small doses. The findings ... funded by the Cancer Research UK. They analysed 1,410 women ...
... driving skills of motorist has resulted in over 4,000 people ... the last three years// , said a senior Delhi Police ... around 1,500 sq km and it is difficult to control ... not up to the mark," Qamar Ahmed, joint commissioner, traffic, ...
... here who have been protesting the central government decision ... have sought// President A.P.J. Abdul Kalam's permission for self-immolation. ... seeking his "permission to immolate themselves", informed Ashutosh Dixit, ... of the junior doctors sitting on a relay hunger ...
... of alcohol may reduce the risk of heart disease than ... that it is applicable only for men and women are ... drinking patterns and heart health among men and women, but ... caution and should not be used to justify potentially harmful ...
... statistics regarding the use of tobacco amongst teenagers, which has ... tobacco and its products. , ,These figures were made ... World No Tobacco Day; on May 31st. This years theme ... or disguise,'' conveying cigarette smoking in any form is extremely ...
... major factor causing health concerns among both the pregnant woman ... that pregnant working// mothers who undergo a lot of stress ... these children were five ounces lighter than the average birth ... case pregnant smokers. These pregnant mothers put themselves through 32 ...
Cached Medicine News:Health News:Road Traffic Accidents Kill 4,000 people in Delhi 2Health News:Daily Intake Of Alcohol Reduces Heart Disease In Men Than Women 2
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Bedrocan Cannabis Corp., ... independent members to its Board of Directors, enhancing ... of the company, a leading licensed producer of ... Internationally, Bedrocan has 13 years, experience in producing ... seven countries, including Canada. As ...
(Date:8/21/2014)... CYBX ) today announced results for the quarter ended ... Operating results for the first quarter of fiscal ... other achievements, include: , Worldwide net product sales of ... net sales of $13.2 million, an increase of 14.5% on ... reached a new high of $58.8 million, an increase of ...
(Date:8/21/2014)... MENLO PARK, Calif. , Aug. 21, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... ("Nat") Ricciardi to the Company,s newly expanded Board of ... now comprises eight directors, three of whom are independent. ... years of experience working with emerging growth companies. He ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... 28, 2011 Tengion, Inc. (Nasdaq: TNGN ) ... to its Board of Directors. Mr. Flora brings to Tengion ... wound healing and surgical device businesses.  He most recently served ... Tengion also announced today that Gary Kurtzman, ...
... SOUTH SAN FRANCISCO, Calif., Sept. 28, 2011 Onyx ... that it has completed the New Drug Application (NDA) ... under the accelerated approval process for carfilzomib, a next ... with relapsed and refractory multiple myeloma. In addition, Onyx ...
Cached Medicine Technology:Tengion Appoints Scott Flora to Board of Directors 2Tengion Appoints Scott Flora to Board of Directors 3Tengion Appoints Scott Flora to Board of Directors 4Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 2Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 3Onyx Pharmaceuticals Submits New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma 4
...
...
Bimanual I&A Cannulas. Curved 45 with a .51mm open-end irrigation port. Facilitates removal of cortical debris between 10-2 o'clock. .80mm x 17.0mm...
...
Medicine Products: